# Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes

*PRI Rank #3 · Topics and Trends in Most Cited Heart Failure Treatment and Management Papers, Class of 2026*

*Canonical URL: https://pri.pepkio.com/top-papers/heart-failure-treatment-and-management/2026/rank-3*

| Field | Value |
| --- | --- |
| Rank | #3 |
| 18m citations | 388 |
| Journal | New England Journal of Medicine |
| Year | 2024 |
| DOI | 10.1056/nejmoa2313917 |
| Corresponding authors | Mikhail N Kosiborod |
| Institution | Saint Luke's Mid America Heart Institute, United States |

**Ranking page:** [Topics and Trends in Most Cited Heart Failure Treatment and Management Papers, Class of 2026](https://pri.pepkio.com/top-papers/heart-failure-treatment-and-management/2026)

**Paper link:** [10.1056/nejmoa2313917](https://doi.org/10.1056/nejmoa2313917)

## Topics

Semaglutide · Heart failure with preserved ejection fraction · Type 2 diabetes · Obesity · GLP-1 receptor agonist · Body mass index · KCCQ Clinical Summary Score · Body weight reduction · 6-minute walk distance · Hierarchical composite endpoint · Win ratio · C-reactive protein · Randomized controlled trial · Placebo-controlled trial · Serious adverse events · Symptom burden · Functional impairment · weight loss · Cardiometabolic disease · Inflammation · Worsening heart failure events · Once-weekly dosing · Secondary endpoints · Obesity-related HFpEF · Clinical trial design · STEP-HFpEF DM trial · Cardiovascular events · Anti-inflammatory effect · Diabetes management · Quality of life

## Cite this ranking

```
Pepkio Research Index (PRI). Topics and Trends in Most Cited Heart Failure Treatment and Management Papers, Class of 2026. https://pri.pepkio.com/top-papers/heart-failure-treatment-and-management/2026. Accessed 2026-07-14.

Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459
```